• Nkarta presented initial NKX019 safety results from 40 patients across five autoimmune diseases at ACR Convergence 2026 on Nov. 11.
• The ongoing Phase 1/2 Ntrust trials reported no deaths, treatment discontinuations due to adverse events or specified immune-related toxicities.
• Severe adverse events primarily affected blood cells, typically linked to preparatory chemotherapy; infusion reactions resolved with supportive care.
• Higher doses showed no increase in adverse event frequency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110700PRIMZONEFULLFEED9875255) on November 11, 2026, and is solely responsible for the information contained therein.